Enjoy complimentary customisation on priority with our Enterprise License!
The injectable drug delivery devices market share is expected to increase by USD 22.29 billion from 2021 to 2026, at a CAGR of 8.48%. This report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches.
This injectable drug delivery devices market research report extensively covers market segmentation by type (advanced injectable drug delivery devices and conventional injectable drug delivery devices) and geography (North America, Europe, Asia, and ROW).
The injectable drug delivery devices market report also offers information on several market vendors, including AstraZeneca Plc, Baxter International Inc., Becton Dickinson and Co., Eli Lilly and Co., Gerresheimer AG, Owen Mumford Ltd., Sanofi SA, SCHOTT AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.
Download the Free Report Sample to Unlock the Injectable Drug Delivery Devices Market Size for the Forecast Period and Other Important Statistics
The rising prevalence of chronic diseases is notably driving the injectable drug delivery devices market growth, although factors such as stringent regulations may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the injectable drug delivery devices industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
The rising prevalence of chronic diseases is one of the key drivers supporting the injectable drug delivery devices market growth. Various biophysiological factors limit the efficacy of targeted therapy for chronic diseases such as diabetes, cancer, atherosclerosis, myocardial ischemia, and others. Therefore, many injectable drug delivery devices are in demand to enhance the drug efficacy for diseases. For instance, long-acting drug delivery systems (LADDSs) treat chronic diseases. The technology delivers the drug molecules into target tissues either through systemic circulation or localized injections. Owing to the rising prevalence of chronic diseases and increasing demand for effective delivery systems will boost the market growth during the forecast period
High growth potential in emerging countries is onw of the key injectable drug delivery devices market trend supporting the market growth. Emerging economies such as China and India have massive untapped market potential for contrast agents and injectable drug delivery devices. This can be mainly attributed to the rising awareness about the benefits of contrast agents and the growing number of medical imaging examinations due to the increasing prevalence of diseases and related risk factors. As of 2019, chronic diseases were the leading cause of early deaths in China. Thus, vendors are increasing their efforts to expand their market penetration in such emerging economies. Such plans of geographical expansions in emerging economies are expected to drive market growth during the forecast period.
Stringent regulations are hindering the injectable drug delivery devices market growth. Regulatory authorities carefully study and evaluate drug-related data before approving it. Safety, efficacy, pharmacological data, pharmacodynamic effects, and drug interactions are some of the key factors that are examined by these authorities. Therefore, a drug failing in any of these criteria is likely to receive a complete response letter (CRL) or may face complete rejection from regulatory agencies. On receiving a CRL, a drug applicant is required to furnish additional data about it. This, in turn, may require additional clinical trials and may increase the R&D expenditure of the drug. This acts as a strong setback for the company and will hinder the market growth during the forecast period.
This injectable drug delivery devices market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the injectable drug delivery devices market encompasses successful business strategies deployed by the key vendors. The injectable drug delivery devices market is fragmented and the vendors are deploying growth strategies such as acquisitions, collaborations, and the launch of new production facilities to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The injectable drug delivery devices market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
For more insights on the market share of various regions Request for a FREE sample now!
45% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for injectable drug delivery devices market in North America. Market growth in this region will be slower than the growth of the market in Asia.
The increasing demand for injectable drug delivery devices due to the high prevalence of chronic diseases will facilitate the injectable drug delivery devices market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the outbreak of COVID-19 slightly declined the growth of the injectable drug delivery devices market in North America. As the number of COVID-19 cases increased, various non-urgent healthcare procedures and research studies, including injectable drug delivery devices, were halted for safety reasons. Moreover, the resumption of business operations with the lifting of lockdown measures and redirecting focus on R&D of injectable drug delivery devices are estimated to boost the market's growth in North America during the forecast period
To gain further insights on the market contribution of various segments Request for a FREE sample
The injectable drug delivery devices market share growth by the advanced injectable drug delivery devices segment will be significant during the forecast period. The pharmaceutical industry is witnessing a rapid rise in biopharmaceuticals, which is increasing the demand for various advanced drug delivery devices, including the advanced injectable devices segment. Hence, the demand for advanced injectable devices is rising strongly in all customer segments, such as pharmaceutical companies, physicians, and patients. This will drive the growth of the segment during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the injectable drug delivery devices market size and actionable market insights on post COVID-19 impact on each segment.
Technavio categorizes the injectable drug delivery devices market as a part of the global healthcare supplies market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the injectable drug delivery devices market during the forecast period.
Our report provides extensive information on the value chain analysis for the injectable drug delivery devices market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
Injectable Drug Delivery Devices Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Decelerate at a CAGR of 8.48% |
Market growth 2022-2026 |
$ 22.29 billion |
Market structure |
Fragmented |
YoY growth (%) |
11.24 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 45% |
Key consumer countries |
US, China, UK, Canada, and Germany |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
AstraZeneca Plc, Baxter International Inc., Becton Dickinson and Co., Eli Lilly and Co., Gerresheimer AG, Owen Mumford Ltd., Sanofi SA, SCHOTT AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
***1. Executive Summary
**1.1 Market Overview
*Exhibit 01: Key Finding 1
*Exhibit 02: Key Finding 2
*Exhibit 03: Key Finding 3
*Exhibit 04: Key Finding 5
*Exhibit 05: Key Finding 6
*Exhibit 06: Key Finding 7
*Exhibit 07: Key Finding 8
***2. Market Landscape
**2.1 Market ecosystem
*2.1.1 Parent market
*Exhibit 08: Parent market
*Exhibit 09: Market Characteristics
**2.2 Value chain analysis
*Exhibit 10: Value chain analysis: Healthcare supplies
*2.2.1 R&D
*2.2.2 Inputs
*2.2.3 Operations
*2.2.4 Outbound logistics
*2.2.5 Marketing and sales
*2.2.6 Post-sales and services
*2.2.7 Industry innovations
***3. Market Sizing
**3.1 Market definition
*Exhibit 11: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 12: Market segments
**3.3 Market size 2021
**3.4 Market outlook: Forecast for 2021 - 2026
*3.4.1 Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
*Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 15: Five forces analysis 2021 & 2026
**4.2 Bargaining power of buyers
*Exhibit 16: Bargaining power of buyers
**4.3 Bargaining power of suppliers
*Exhibit 17: Bargaining power of suppliers
**4.4 Threat of new entrants
*Exhibit 18: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 19: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 20: Threat of rivalry
**4.7 Market condition
*Exhibit 21: Market condition - Five forces 2021
***5. Market Segmentation by Type
**5.1 Market segments
*The segments covered in this chapter are:
*Exhibit 22: Type - Market share 2021-2026 (%)
**5.2 Comparison by Type
*Exhibit 23: Comparison by Type
**5.3 Advanced injectable drug delivery devices - Market size and forecast 2021-2026
*Exhibit 24: Advanced injectable drug delivery devices - Market size and forecast 2021-2026 ($ million)
*Exhibit 25: Advanced injectable drug delivery devices - Year-over-year growth 2021-2026 (%)
**5.4 Conventional injectable drug delivery devices - Market size and forecast 2021-2026
*Exhibit 26: Conventional injectable drug delivery devices - Market size and forecast 2021-2026 ($ million)
*Exhibit 27: Conventional injectable drug delivery devices - Year-over-year growth 2021-2026 (%)
**5.5 Market opportunity by Type
*Exhibit 28: Market opportunity by Type
***6. Customer landscape
**6.1 Overview
*Exhibit 29: Customer landscape
***7. Geographic Landscape
**7.1 Geographic segmentation
*The regions covered in the report are:
*Exhibit 30: Market share by geography 2021-2026 (%)
**7.2 Geographic comparison
*Exhibit 31: Geographic comparison
**7.3 North America - Market size and forecast 2021-2026
*Exhibit 32: North America - Market size and forecast 2021-2026 ($ million)
*Exhibit 33: North America - Year-over-year growth 2021-2026 (%)
**7.4 Europe - Market size and forecast 2021-2026
*Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)
*Exhibit 35: Europe - Year-over-year growth 2021-2026 (%)
**7.5 Asia - Market size and forecast 2021-2026
*Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)
*Exhibit 37: Asia - Year-over-year growth 2021-2026 (%)
**7.6 ROW - Market size and forecast 2021-2026
*Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)
*Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)
**7.7 Key leading countries
*Exhibit 40: Key leading countries
**7.8 Market opportunity by geography
*Exhibit 41: Market opportunity by geography ($ million)
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Rising prevalence of chronic diseases
*8.1.2 Growth in the biologics market
*8.1.3 Digitalization in the healthcare system
**8.2 Market challenges
*8.2.1 Stringent regulations
*8.2.2 Product recall
*8.2.3 Risk of needlestick injuries
*Exhibit 42: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 High growth potential in emerging countries
*8.3.2 Self-injectable drug delivery devices
*8.3.3 Increasing investments in pharmaceutical research and development
***9. Vendor Landscape
**9.1 Overview
*Exhibit 43: Vendor landscape
**9.2 Landscape disruption
*Exhibit 44: Landscape disruption
*Exhibit 45: Industry risks
**9.3 Competitive landscape
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 46: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 47: Market positioning of vendors
**10.3 AstraZeneca Plc
*Exhibit 48: AstraZeneca Plc - Overview
*Exhibit 49: AstraZeneca Plc - Product and service
*Exhibit 50: AstraZeneca Plc – Key news
*Exhibit 51: AstraZeneca Plc - Key offerings
**10.4 Baxter International Inc.
*Exhibit 52: Baxter International Inc. - Overview
*Exhibit 53: Baxter International Inc. - Business segments
*Exhibit 54: Baxter International Inc. – Key news
*Exhibit 55: Baxter International Inc. - Key offerings
*Exhibit 56: Baxter International Inc. - Segment focus
**10.5 Becton Dickinson and Co.
*Exhibit 57: Becton Dickinson and Co. - Overview
*Exhibit 58: Becton Dickinson and Co. - Business segments
*Exhibit 59: Becton Dickinson and Co. – Key news
*Exhibit 60: Becton Dickinson and Co. - Key offerings
*Exhibit 61: Becton Dickinson and Co. - Segment focus
**10.6 Eli Lilly and Co.
*Exhibit 62: Eli Lilly and Co. - Overview
*Exhibit 63: Eli Lilly and Co. - Business segments
*Exhibit 64: Eli Lilly and Co. - Key offerings
*Exhibit 65: Eli Lilly and Co. – Key news
*Exhibit 66: Eli Lilly and Co. - Segment focus
**10.7 Gerresheimer AG
*Exhibit 67: Gerresheimer AG - Overview
*Exhibit 68: Gerresheimer AG - Business segments
*Exhibit 69: Gerreshimer AG – Key news
*Exhibit 70: Gerresheimer AG - Key offerings
*Exhibit 71: Gerresheimer AG - Segment focus
**10.8 Owen Mumford Ltd.
*Exhibit 72: Owen Mumford Ltd. - Overview
*Exhibit 73: Owen Mumford Ltd. - Product and service
*Exhibit 74: Owen Mumford Ltd. - Key offerings
**10.9 Sanofi SA
*Exhibit 75: Sanofi SA - Overview
*Exhibit 76: Sanofi SA - Business segments
*Exhibit 77: Sanofi SA – Key news
*Exhibit 78: Sanofi SA - Key offerings
**10.10 SCHOTT AG
*Exhibit 79: SCHOTT AG - Overview
*Exhibit 80: SCHOTT AG - Business segments
*Exhibit 81: SCHOTT AG – Key news
*Exhibit 82: SCHOTT AG - Key offerings
*Exhibit 83: SCHOTT AG - Segment focus
**10.11 Teva Pharmaceutical Industries Ltd.
*Exhibit 84: Teva Pharmaceutical Industries Ltd. - Overview
*Exhibit 85: Teva Pharmaceutical Industries Ltd. - Business segments
*Exhibit 86: Teva Pharmaceutical Industries Ltd. - Key offerings
*Exhibit 87: Teva Pharmaceutical Industries Ltd. - Segment focus
**10.12 Viatris Inc.
*Exhibit 88: Viatris Inc. - Overview
*Exhibit 89: Viatris Inc. - Business segments
*Exhibit 90: Viatris Inc. – Key news
*Exhibit 91: Viatris Inc. - Key offerings
*Exhibit 92: Viatris Inc. - Segment focus
***11. Appendix
**11.1 Scope of the report
*11.1.1 ????Market definition
*11.1.2 Objective
*11.1.3 Notes and caveats
**11.2 Currency conversion rates for US$
*Exhibit 93: Currency conversion rates for US$
**11.3 Research Methodology
*Exhibit 94: Research Methodology
*Exhibit 95: Validation techniques employed for market sizing
*Exhibit 96: Information sources
**11.4 List of abbreviations
*Exhibit 97: List of abbreviations
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.